Search

everythinglearnresearchcommunity

for

Search:↓

A 20-year-old has been using minoxidil for 6 months and is starting finasteride to address hair loss. They express concern about whether their hair can regrow.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Microneedling is more effective when combined with minoxidil, especially for temple regrowth, but is considered near-useless on its own. Users suggest combining microneedling with oral minoxidil and dutasteride for better results, while some caution against potential scalp damage.

Hair loss impacts mental health and should be covered by healthcare, with treatments like finasteride, dutasteride, and minoxidil being affordable and effective. Some argue hair loss is cosmetic and shouldn't be funded, while others highlight its broader health implications.

A 42-year-old is using minoxidil for 1.5 years, recently started finasteride, and plans to use a microneedling pen on their scalp. They are seeking advice on regrowing hair.

The conversation discusses hair regrowth possibilities using finasteride, minoxidil, microneedling, and dutasteride, with the user experiencing improvement from NW4 to NW2. Achieving NW0 is deemed unrealistic, but further regrowth may be possible with patience and potentially a hair transplant.

Theo Von discussed undergoing a hair transplant and is reportedly using finasteride. Joe Rogan also had hair transplants but faced challenges due to thin donor areas and not using finasteride.

King Thutmose IV's hair retention is humorously speculated to be due to treatments like finasteride, minoxidil, or other unconventional methods. The discussion includes jokes about genetics, ancient practices, and modern hair loss solutions.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.